Yes, Wainua (epatrizodib) is FDA-approved for treating polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.[1]
How does Wainua work for ATTR polyneuropathy?
Wainua is a TTR stabilizer that binds to transthyretin (TTR) protein in the blood to prevent its misfolding and deposition as amyloid in nerves and tissues. This reduces polyneuropathy symptoms like numbness, pain, and weakness. Approval followed the phase 3 HELIOS-B trial, where it slowed neuropathy progression by 52% versus placebo over 12 months.[1][2]
Who qualifies for Wainua treatment?
It's indicated for adults with confirmed hATTR amyloidosis and polyneuropathy. Use requires genetic testing to verify TTR mutations. It's not approved for wild-type ATTR cardiomyopathy or asymptomatic cases.[1]
When did Wainua get approved and what's the dosing?
The FDA approved Wainua in October 2024 for monotherapy. Patients receive 225 mg subcutaneously every 4 weeks after an optional loading dose.[1]
How does Wainua compare to other ATTR polyneuropathy drugs?
| Drug | Mechanism | Approval Year | Key Trial Result |
|------|-----------|---------------|-----------------|
| Wainua (epatrizodib) | TTR stabilizer | 2024 | 52% neuropathy progression reduction (HELIOS-B)[2] |
| Onpattro (patisiran) | TTR silencer (siRNA) | 2018 | 56% mNIS+7 improvement (APOLLO)[3] |
| Amvuttra (vutrisiran) | TTR silencer (siRNA) | 2022 | 51% progression reduction (HELIOS-A)[3] |
Wainua offers monthly dosing without IV infusion, unlike patisiran. No head-to-head trials exist.[2][3]
What side effects do patients report?
Common issues include arthralgia (30%), back pain (15%), and extremity pain (14%). Serious risks involve vitamin A deficiency (monitor/supplement) and infusion reactions. No black box warnings.[1]
When does Wainua's patent protection end?
Core composition patents expire around 2038-2040, with pediatric exclusivity possibly extending to 2041. Challenges from generics are not yet public.[4]
[1]: FDA Label for Wainua
[2]: NEJM: HELIOS-B Trial
[3]: FDA Labels: Onpattro/Amvuttra
[4]: DrugPatentWatch: Wainua Patents